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  21 
SUMMARY 22 
 23 
Aim: To examine patients’ stated preferences to persist with medicines and to explore the influence of 24 
psychosocial and sociocognitive factors. 25 
 26 
Methods: Community-dwelling, hypertensive patients recruited from 9 European countries were 27 
invited to complete a discrete choice experiment (DCE) with attributes for treatment benefits, mild yet 28 
common adverse drug reactions (ADR), rare but potentially life-threatening ADR and dosing 29 
frequency. Patients responded to the binary-choice of which medicine would they be most likely to 30 
continue taking. Data were analysed using a random effects logit model. 31 
 32 
Results: 2549 patients from Austria (n=321), Belgium (n=175), England (n=315), Germany (n=266), 33 
Greece (n=288), Hungary (n=322), Netherlands (n=231), Poland (n=312) and Wales (n=319) 34 
completed the DCE.   All attributes significantly influenced patients’ stated preference to persist with 35 
medications (p<0.05).  Patients were willing to accept decreases in treatment benefits of: 50.6 36 
percentage points (95%CI: 46.1-57.9) for a very rare (as opposed to rare) risk of severe ADR; 28.3 37 
percentage points (95%CI: 25.2-33.1) for a once-daily instead of twice-daily dosing; and 0.74 38 
percentage points (95%CI: 0.67-0.85) for a 1% point reduction in mild ADR. Models accounting for 39 
psychosocial and sociocognitive characteristics were significantly different from the base case. 40 
 41 
Conclusion: Patients’ intention to persist with treatment was associated with their willingness to trade 42 
potential benefits, harms, and dosing frequency.  Psychosocial and sociocognitive factors influenced 43 
the extent of trading.  The utility model may have value in assessing patients’ likelihood of persisting 44 
with medicines, and to tailor treatment to maximise persistence. 45 
  46 
What is known about this subject?  47 
1. Persistence with medicines can be considered as an outcome of a conscious decision patients 48 
make about whether the continued taking of the medication will increase their utility 49 
2. Discrete choice experiments of implementation of dosing have found that patients are willing to 50 
accept adverse events in exchange for increase benefit. 51 
What this study adds 52 
1. Within our multinational DCE, hypertensive patients’ intentions to persist with medication were 53 
influenced by treatment benefit, harm and dosing frequency  54 
2. Psychosocial and sociocognitive factors changed the extent to which trade-offs were made 55 
among these attributes  56 
3. The findings may have value in assessing patients’ likelihood of persisting with medicines, and in 57 
the development of adherence-enhancing interventions  58 
INTRODUCTION 59 
Medication adherence encompasses the processes of initiation, implementation of dosing and 60 
persistence [1]. Reduced persistence with prescribed treatment is prevalent, with median length of 61 
time between patients’ initiation of treatment for chronic diseases and their last dose being typically in 62 
the order of 1 year [2], despite failure to continue treatment having a detrimental effect on health [3].  63 
Reasons for the premature discontinuation of medicines are varied, and include factors related to 64 
patients, such as their beliefs and socioeconomic characteristics; the condition and its treatment; 65 
healthcare professionals and health systems [3,4]. There is emerging evidence of the role of 66 
behavioural economic theories in explaining patients’ choice to persist with their prescribed medicines 67 
[5].  This is based on a notion that persistence with medications may be an outcome of a decision 68 
patients consciously make about whether the continued taking of their medication will increase their 69 
utility [6]. That is, if patients’ utility (satisfaction) is maximised through taking their medications, their 70 
likelihood of persisting increases; but conversely if patients maximise their utility by not taking their 71 
medications, they will discontinue treatment. 72 
Patients’ utility may be examined using stated preference techniques, such as the discrete choice 73 
experiment (DCE) [7].  DCEs are an attribute-based survey measure underpinned by a Lancastrian 74 
view of utility which contends that goods and services (or medicines in this case) can be described by 75 
their characteristics or attributes and that the utility yielded by a medicine is a function of its various 76 
attributes [8].  Choices reveal information about the relative importance of each attribute, willingness 77 
to trade them, and total utility which patients aim to maximise. 78 
DCEs represent a particularly effective method of eliciting preferences regarding health processes 79 
and outcomes that have gained extensive use in several contexts, including patients’ preferences for 80 
medicines [9,10], but few empirical studies have made specific reference to the process of adherence 81 
to medication [11-13]. Hauber et al [11] conducted a study of treatment preferences and adherence to 82 
oral glucose-lowering agents amongst individuals with type 2 diabetes and found that while patients 83 
were willing to accept some adverse events in exchange for better glucose control, stated adherence 84 
would reduce with increasing risk of weight gain or myocardial infarction.  Using a choice-format 85 
stated-preference survey, Johnson et al. [12] identified severity of depressive episodes, weight gain 86 
and the cognitive effects of treatments for bipolar disorder to affect patients’ likelihood to adhere.  87 
The view that non-adherence may be considered a rational behaviour that reveals patient 88 
preferences, adds to more established health psychology research studies.  Within health and social 89 
psychology there exist several theoretical frameworks and models for explaining variation in health-90 
related behaviours, which can be applied to persistence with medications [14].  Sociocognitive theory 91 
assumes that persistence is motivated by outcome expectancies and goals (such as improved 92 
health), which are determined by individuals’ attitudes and beliefs [15-17].  Models within 93 
sociocognitive theory that have been applied to persistence with medications include the Health Belief 94 
Model [18-19] and The Theory of Planned Behaviour [20].  In this context, the Health Belief Model 95 
postulates the likelihood of persistence is increased if the perceived threat of illness from sub-optimal 96 
persistence is high, the benefit of medicines-taking is greater than the barriers to medicines-taking, 97 
and cues to action (e.g. reminders) are in place.  The Theory of Planned Behaviour suggests an 98 
individual’s intention to persist with medication increases if the perceived consequences are high 99 
(attitudes towards behaviour and outcome expectancies are positive), they have strong positive 100 
beliefs about what others expect (perceived social norms); and they perceive a high level of personal 101 
control / self-efficacy with regards to persisting, even when facing barriers; this will depend on their 102 
perception of internal resources (e.g. knowledge) and external resources (e.g. social support).   103 
 104 
A more dynamic link between cognitions, motivation and behaviour can be explored using self-105 
regulation theory [21].  Self-regulation theory describes the individual as an active problem solver and 106 
describes the cognitive and behavioural process by which individuals monitor and adjust their 107 
medication taking as the perceived solution to the problem of illness and its consequences [17].  108 
Illness representations or beliefs, together with treatment beliefs, shape coping responses e.g. 109 
persistence with medications.  Beliefs about a particular illness and state of ill health are thought to 110 
form around five domains:  Identity: signs and symptoms; Timeline: ideas about the time-frame of a 111 
condition (acute, chronic, cyclical); Cause: perception of cause (internal, external, stable, unstable 112 
etc.); Consequences: expected outcomes (physical, psychological and social); and, Control / cure: 113 
beliefs about potential cure and (internal/external) control.  The contribution of the models described 114 
can be measured using self-report questionnaires for each component e.g. Barriers in the Theory of 115 
Planned Behaviour, or Illness consequences within Illness Perception Questionnaire.  116 
Concurrent assessment of influences on patients’ decisions to persist with a medication in terms of 117 
the utility they derive from medication characteristics, and theory driven psychosocial characteristics 118 
associated with medication preferences, increases the possibilities for interventions which could be 119 
both medicine and person-based.  We are unaware of any study in which a range of health 120 
psychology theories have been tested simultaneously alongside preference elicitation methods in 121 
relation to medication persistence. 122 
This study aims to (i) assess how patients from across Europe value the key attributes of medicines in 123 
their stated decision to persist with taking them and to examine the trade-off between potential 124 
benefit, harm and convenience; (ii) explore the relationship between these preferences and 125 
psychosocial and sociocognitive characteristics. 126 
 127 
METHODS 128 
The study involved a multi-national, web-based survey of hypertensive adult patients containing a 129 
DCE designed to elicit the preferences of patients for attributes of a hypothetical medication.  The 130 
survey was piloted and ethically approved for eleven European countries: Austria, Belgium, England, 131 
France, Germany, Greece, Hungary, Netherlands, Poland, Portugal, and Wales.  Patients were 132 
eligible for the study if they self-reported as being 18 years or older, diagnosed by a doctor as having 133 
hypertension that lasted at least 3 months, currently prescribed antihypertensive medication, and 134 
personally responsible for administering their medication.  Respondents were excluded if they were 135 
aged less than 18 years, declared a psychiatric disorder, or lived in a nursing home or similar facility 136 
where they were not responsible for their own medicines taking.  The target sample was for a 137 
minimum of 100 respondents per country (consistent with DCE studies [9,10]) up to a maximum of 138 
323 patients per country [22].  Respondents were principally recruited using advertisements in 139 
community pharmacies.  Additional strategies included advertisements in hypertension clinics 140 
(Hungary), GP surgeries (Hungary and Poland) and local press (England and Wales).  The survey 141 
was anonymous, hosted online and restricted to one respondent per Internet Protocol address. 142 
 143 
DCE attributes, levels, and experimental design 144 
We identified a list of potential attributes from 18 DCE studies of medicinal products identified in a 145 
systematic review [9].  Attributes identified were categorised as follows:  mild adverse drug reactions 146 
(n=14 studies), treatment outcome (n=13), severe adverse drug reactions (n=6), dose related (n=5), 147 
duration of treatment (n=4), location of treatment (n=3), cost (n=3), route of administration (n=1), 148 
quality of life (n=1).  The four most commonly used attributes were selected:  treatment benefit, risk of 149 
common mild adverse drug reactions (ADRs), risk of rare but potentially life-threatening ADRs and 150 
dosage frequency (table 1).   151 
We hypothesised that benefits would have a positive influence on patients’ stated intention to persist 152 
with treatment, while increased risk of harms and dose frequency would be negative.   153 
Insert Table 1 here 154 
Each attribute was set to have three levels, representative of treatments used commonly for the 155 
management of chronic diseases. These were set at plausible values with a range sufficient to 156 
encourage respondents to trade, and limit potential dominance (Table 1), while allowing for scenarios 157 
(e.g. for improved benefit) to be modelled. For the DCE to be broadly generalizable across many 158 
common treatments, we used a hypothetical scenario of an unlabelled medicine and respondents 159 
were not given information on any specific condition or disease area.  The question posed was: Which 160 
medicine would you be most likely to continue taking?  Figure 1 provides an example of the pairwise 161 
choice used in the experiment. 162 
Insert Figure 1 here 163 
The number of possible choice scenarios in a full factorial design was 34 = 81. As this would pose too 164 
great a burden on respondents, a fractional factorial design was selected with 9 profiles from a 165 
published design catalogue [23]. Binary choices were created using the fold-over method which 166 
replaces each attribute level with its opposite [24]. The attribute and question order was randomised 167 
to avoid left or right selection bias.  Rational trading was tested by examining responses to a 168 
dominant profile which had a lower risk of mild ADR, lower dosage frequency, higher treatment 169 
benefit and lower risk of severe ADR.   170 
 171 
Survey of psychosocial and sociocognitive factors 172 
Validated self-report instruments were used to assess sociocognitive determinants of adherence [22].  173 
Illness representations were measured using the Brief Illness Perception Questionnaire (B-IPQ) [25].  174 
Patient beliefs in the necessity and concerns of medications were measured using the Beliefs about 175 
Medicines Questionnaire [26].  Constraints and facilitators of adherence were measured using barrier 176 
and social support subscales of the BRIGHT questionnaire [27-28].  Attitudinal and belief components 177 
of the Theory of Planned Behaviour (TPB) were scored on a 5-point Likert scale [29-30].  Self-178 
reported adherence was measured using the Morisky questionnaire [31] which categorises 179 
participants as being non-adherent if they respond with a “yes” to at least one of four questions 180 
posed; and the Medication Adherence Rating Scale (MARS) which results in a continuous score for 181 
adherence (range 5-25) [32].  Details of the psychosocial measures used in the exploratory analysis 182 
are provided in Appendix 1.  The full survey content is detailed elsewhere [22]. 183 
 184 
Translation 185 
Measures that were not validated and available in the required language were translated into the 186 
appropriate languages (and back-translated for checks of compatibility with the English version) using 187 
accredited translators who were native speakers of the target languages and fluent in English. 188 
Descriptions of ADR prevalence were taken from the European Medicines Agency’s standard text for 189 
summaries of product characteristics, which is available in all European languages. 190 
 191 
Data analysis 192 
Results of the DCE were analysed in STATA (version 10; StataCorp LP, College Station, TX) using a 193 
random effects logit model that allowed for repeated observations from the same respondent: 194 
U = β0 + β1SEVERE_ADR + β2DOSE + β3BENEFIT + β4MILD_ADR + ε 195 
U = utility derived by individual  196 
β0 = constant term  197 
βi = estimated coefficient for each attribute (variable)  198 
ε = error term  199 
Treatment benefit and risk of mild ADR were included in the analysis as linear continuous variables.  200 
We explored the assumption of linearity for frequency of dose and risk of severe ADR, using effects 201 
coding and plotting the resulting size of the coefficient against the level of each attribute.  The level of 202 
the base case was calculated using the estimated levels: e.g. 203 
βvery rare SEVERE_ADR = - (βrare SEVERE_ADR + βuncommon SEVERE_ADR) 204 
The DCE contained two value attributes: treatment benefit and risk of common, mild ADR, that were 205 
used to compare the rate at which patients were willing to give up a unit change in benefit or harm in 206 
exchange for a unit change in another, whilst maintaining the same utility (marginal rates of 207 
substitution, MRS).  95% confidence intervals were calculated by Bootstrapping with 1,000 208 
replications.  Lexicographic preferences were explored by looking for left or right hand bias, using 209 
counts of how many respondents continually selected medicine A or B. The influence of psychosocial 210 
and sociocognitive factors on preferences for persistence was assessed using exploratory subgroup 211 
analyses.  Subgroups were selected for analysis if they: (i) had a statistically significant association 212 
with adherence (as defined by Morisky or MARS) [22]; and (ii) were confirmed as significant predictors 213 
of persistence in other published studies [14].  Log likelihood ratio tests of the base case regression 214 
and the models comprising the two subgroups were performed at a 5% level of significance.  If the 215 
subgroup model was significantly different, the MRS for harms and benefits were calculated for each 216 
category within the subgroup.  217 
 218 
 219 
RESULTS  220 
The analysis was restricted to nine countries that reached the target sample size. There was an 221 
inadequate level of available research support in France and Portugal that resulted in low response 222 
(n=11, n=33 respectively) thus these were excluded. Eighty-nine percent (n=2,549) of people who 223 
started the survey completed at least one DCE question. These were from Austria (n=321), Belgium 224 
(n=175), England (n=315), Germany (n=266), Greece (n=288), Hungary (n=322), Netherlands 225 
(n=231), Poland (n=312) and Wales (n=319). 226 
 227 
Sample characteristics 228 
Participants’ characteristics are presented in Table 2. Respondents were split almost equally 229 
according to gender (51% male) and employment status (52% employed), had a median age of 60 230 
years, and were prescribed a median of 3 different medicines per day. The majority of patients (54%) 231 
were prescribed medicines that required more than once-daily dosing. 232 
Insert Table 2 here 233 
Magnitude and statistical significance of attributes 234 
Among respondents to the DCE, 91.2% selected the dominant choice while only 2.5% of respondents 235 
showed lexicographic preferences, consistently choosing medicine A (1.77%) or B (0.76%). 236 
All four attributes influenced respondents’ stated intention to persist with treatment (p<0.01) (Table 3).   237 
Respondents were most likely to persist with the treatment offering greatest benefit (β=0.031), least 238 
risk of mild but common ADRs (β=-0.023), or severe but rare ADRs (β=1.553), and the least frequent 239 
dosing regimen (β=0.869).  The signs and direction of the regression coefficients were consistent with 240 
expectation. 241 
Insert Table 3 here 242 
All else being equal, the odds of patients stating that they would continue taking their medicines 243 
increased by 3% for every 1 percentage point increase in the chance of treatment benefits, and 244 
increased 2% for every 1 percentage point decrease in the risk of common mild side-effects.  A 245 
medicine with the lowest risk of severe ADR (very rare) increased the odds of persistence four-fold, 246 
and the lowest dose frequency (once daily) more than two-fold.   247 
 248 
Comparing preferences 249 
Marginal rates of substitution, using treatment benefit as the value attribute, suggest that patients 250 
were willing to forego improvements in treatment benefits in order to: reduce the risk of severe ADR 251 
(forego 50.6 percentage point improvement in treatment benefit for a ‘very rare’ risk of severe of ADR 252 
as opposed to a rare risk); reduce the frequency of dosing (forego 28.3 percentage point improvement 253 
in treatment benefit for once-daily dosage frequency as opposed to twice daily); and to reduce the risk 254 
of common mild side-effects (forego 7.4 percentage point improvement of treatment benefit for a 10 255 
percentage point reduction in mild ADR) (Table 4).  When considering harm as the value attribute, 256 
respondents were also willing to accept an increase in risk of mild ADR to avoid severe ADR (68.6 257 
percentage point increase in risk of mild side-effects for a ‘very rare’ risk of severe ADR as opposed 258 
to rare); and to move to a less frequent dosing schedule (38.4 percentage point increase in risk of 259 
mild ADR for once daily dose frequency as opposed to twice daily). 260 
Insert Table 4 here 261 
Exploratory analysis 262 
Regressions controlling for psychosocial variables were significantly different from the base-case 263 
regression in 10/12 cases (Appendix 2), but in each case, all four attributes were significant and in the 264 
expected directions.  265 
 266 
Respondents’ willingness to trade treatment benefit for once daily dosing, as opposed to twice daily, 267 
was significantly higher for respondents who were unlikely to take their medicines regularly.  These 268 
respondents, who had low intentions, were willing to forgo an additional 29.9 percentage point benefit 269 
to take medication once, rather than twice a day (i.e. Appendix 2; MRS of lower intentions 49.97 270 
minus MRS of high intentions 20.06).  Individuals with high concerns about medicines were also 271 
willing to forgo an additional benefit to take medication once, rather than twice a day (22.2 percentage 272 
points); as where those who lacked confidence in their medicines-taking i.e. those with low self-273 
efficacy (16.6 percentage points) and, those with higher illness concern (willing to forgo a 15.5 274 
percentage point improvement in benefit to take medication once, rather than twice a day).   275 
 276 
Respondents’ willingness to trade treatment benefit for the lowest risk of ADR (very rare) opposed to 277 
a rare risk was significantly higher for respondents who were (i) unlikely to take their medicines 278 
regularly (people with low intention were willing to forgo a 32.4 percentage point additional benefit for 279 
a very rare risk of severe ADR, than those categorised as high TPB intentions); (ii) demonstrated high 280 
illness concern (24.5 percentage points); and (iii) had high concerns about medicines (23.8 281 
percentage points).  282 
 283 
 284 
DISCUSSION  285 
The results of the study suggest that, in addition to treatment benefits, patients place a high value on 286 
reduced risk of severe (but relatively rare) ADRs and less frequent dosing when stating that they 287 
choose to continue taking a medicine. Stated preference to persist is therefore associated with the 288 
willingness to trade potential benefits for reduced harm and increased convenience. The total utility 289 
produced by different combinations of these attributes may have value in assessing patients’ 290 
likelihood of persisting with medicines, in the context of health care provider-patient communications, 291 
and the personalisation of medicines, or formulations thereof, to maximise persistence.    292 
 293 
This study has shown that the evidence-based medicine model of health maximisation via use of 294 
treatments with the highest expected net benefit may not necessarily result in the best outcome for 295 
patients if there is misalignment in preferences.  Persistence with medications can be considered as 296 
an outcome of a decision patients make about whether the continued taking the medication will 297 
increase their utility [6].  Maximising utility may therefore increase persistence, which may lead to 298 
better health outcomes – even when using a less effective treatment.  Our analysis therefore 299 
suggests a mechanism via which the prescribing of alternative treatments might improve persistence 300 
and hence health outcome.  We have also found that patients’ trade-offs between benefits, harm and 301 
convenience are influenced by psychosocial and sociocognitive factors.  Interventions to improve 302 
persistence, grounded in theory and targeted towards psychosocial variables (e.g. barriers to 303 
medicines, self-efficacy / confidence in medicines taking) may therefore improve the probability of 304 
persistence directly [22], and indirectly through changing patients’ preferences for medicines-related 305 
attributes. This study illustrates the potential for improvements in sociocognitive factors to increase 306 
the utility of routinely prescribed drugs and thus encourage persistence.  Further research is 307 
necessary to design and provide evidence on the efficacy of potential interventions.  Our findings 308 
suggest that several factors influence persistence, however a simple intervention, such as a guided 309 
conversation or a medicines review, could enable health care professionals to identify barriers to 310 
medicines taking and assess how other people influence perceptions of medicines (subjective norms), 311 
in order increase an individual’s self-efficacy via education or counselling.   312 
 313 
Previous DCEs of preferences for medicines reveal that patients are willing to trade benefit for 314 
reduced harm [9,10]. In the context of adherence, a DCE by Mohamed et al. [13] showed that lower 315 
frequency of administration, shorter administration times, and milder ADR appear to improve stated 316 
adherence to antibiotic treatment of CF lung infections. A study of patients with HIV, using a modified 317 
adaptive conjoint analysis, identified pill burden, dosing frequency, and adverse events as having the 318 
greatest impact on patients’ perceived ability to adhere to antiretroviral medication regimens [33].  319 
 320 
To our knowledge this is the first study of preferences for persistence with medication to survey a 321 
large multi-national sample; and, the first study to measure both stated preferences and a wide range 322 
of psychosocial factors concurrently.  The DCE was generic, based on previously tested actionable 323 
attributes and used European Medicines Agency data and terminology where possible to enable 324 
general application.  The selection of psychosocial and sociocognitive factors tested alongside the 325 
DCE attributes was guided by theory and based on empirical evidence. 326 
 327 
There were a number of limitations. Firstly, patients self-selected to participate in the study and we 328 
must therefore acknowledge the risk of selection bias which may influence the results insofar as only 329 
people who were actively interested in expressing their views on their medicines taking behaviour 330 
participated, which may reduce the external validity of our findings.   Secondly, our study was 331 
restricted to four attributes to cover benefits, harms and convenience; findings from other studies of 332 
preferences for medications (not persistence with) suggest that attributes such as route of 333 
administration [34], quality of life, location / provider, duration of treatment, among others, may also 334 
have a significant influence on preference.  The risk attributes were also presented as probabilities 335 
with no indication of frequency or time horizon.  It is acknowledged, however, that trading multiple 336 
attributes is cognitively challenging [35]. We aimed to minimise this by piloting the DCE extensively 337 
and by using two methods of displaying risk. Event frequencies were supplemented by pictograms 338 
which were intended to aid interpretation by depicting probabilities graphically and colour-coding 339 
positive and negative effects. Respondents find it much easier to understand pictorial representations 340 
than presenting probabilities in the form of 1 in X chance [36]. Thirdly, the respondents were 341 
diagnosed with hypertension whereas the DCE was aimed to cover a broad spectrum of 342 
pharmaceuticals..  The DCE was not amenable to treatments for hypertension as they are mainly 343 
once daily.  Fourthly, the length of the survey (135 items) represents a further limitation, but 344 
completion rates were high as the DCE was purposely put towards the beginning of the survey before 345 
participants were asked to complete any items that may have conditioned their choice [22]. Finally, as 346 
with any stated preference study, the findings need to be confirmed by studies of revealed preference. 347 
 348 
Patients were willing to trade potential benefits, harms, and convenience in responding that they 349 
would persist with treatment. Potentially alterable, psychosocial factors influence the extent of the 350 
trade-offs between these attributes.  Persistence may therefore be enhanced directly, through 351 
selection of medicines meeting preferred levels of attributes; or, indirectly through targeting modifiable 352 
psychosocial factors that affect trade-off choices.   The novel finding of an interaction between 353 
patients’ stated preferences to persist with medication and their sociocognitive characteristics (i.e. 354 
high/low illness concerns, high/low self-efficacy etc.) provides a basis for synergistically effective 355 
approaches aimed to change behaviour (e.g. to increase self-efficacy) and treatment selection (e.g. 356 
reduced dose frequency). 357 
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Figure 1.  Example of pairwise choice 481 
 482 
We would like you to imagine that you have been prescribed a new medicine that you should 483 
continue taking until your doctor advises otherwise.  In the following questions the characteristics of 484 
two alternative medicines will be described to you, please indicate which medicine you would be 485 
most likely to continue taking, ‘Medicine A or Medicine B’. 486 
 487 
 Medicine A Medicine B 
Mild side-effects  
e.g. feeling sick, 
diarrhoea 
5 in 10 
 
1 in 10 
 
Number of times you 
need to take the 
medicine 
Once a day Twice a day 
Treatment benefits  
4 in 20 
 
 
1 in 20 
 
 
Potentially life-
threatening side-
effects 
Uncommon:  1 person in 100 Very Rare:  1 person in 10,000 
 
Which medicine 
would you be most 
likely to continue 
taking? 
  
 488 
  489 
Table 1.  Attributes and Levels 490 
Attribute 
name 
Attribute 
description  
Level description Rationale for levels  
Benefit Treatment 
benefits 
1 in 20  
2 in 20  
4 in 20  
Based on typical Numbers Needed to Treat for 
treatment for chronic conditions (e.g. 
hypertension, diabetes, ulcerative colitis) 
 
Dose Number of times 
you need to take 
the medicine 
Once a day 
Twice a day 
Four times a day 
The majority of chronic disease treatments are in 
the range of once to four times daily dosing 
Mild ADR Mild side-effects  
e.g. feeling sick, 
diarrhoea 
1 in 10 
3 in 10 
5 in 10 
 
Gastrointestinal irritation is a common ADR for 
many treatments. Frequency based on 
representative range 
Severe ADR Potentially life-
threatening side-
effects 
Very rare: 1 in 10,000 
Rare: 1 in 1,000  
Uncommon: 1 in 100  
Likelihood of life-threatening ADRs are typically 
uncommon to very rare 
 491 
  492 
Table 2. Values of regression variables used to estimate utility and probability of persistence with 5-493 
ASAs for ulcerative colitis 494 
 Drug name References 
 sulfasalazine mesalamine olsalazine balsalazide 
 
Probability of 
remission  
0.37 0.42 0.33 0.24 [35] 
Probability of ADR  0.34 0.13 0.20 0.10 [35] 
Frequency of severe 
ADR (aplastic 
anaemia) 
Very rare Rare Very rare Very rare SmPC 
Maintenance dose 
frequency 
Four times daily  Once a day  Twice a day Twice a day SmPC 
 495 
SmPC summary of product characteristics 496 
  497 
Table 3. Random effects logit model  498 
Attribute Coefficient (95%CI) p-value Odds Ratio 
Severe ADR - Very rare 1.553 (1.469, 1.637)  4.726 
Severe ADR - Rare -0.444 (-0.488, -0.401) 0.0000 0.641 
Severe ADR - Uncommon -1.109 (-1.149, -1.068) 0.0000 0.330 
Dose - Once a day  0.869 (0.776, 0.961)  2.383 
Dose - Twice a day -0.296 (-0.341, -0.250) 0.0000 0.744 
Dose - Four times a day -0.573 (-0.620, -0.526) 0.0000 0.564 
Treatment benefit 0.031 (0.028, 0.034) 0.0000 1.031 
Common mild side-effects -0.023 (-0.024, -0.022) 0.0000 0.978 
Constant 0.452 (0.414, 0.490) 0.0000 1.572 
Number of observations  22277   
Number of groups 2549   
Wald chi2 (6 degrees of freedom) 1465   
Log likelihood -11952.52   
 499 
 500 
  501 
Table 4. Patients’ marginal rates of substitution between treatment benefit or reduction in common 502 
mild side-effects and other attributes 503 
 Marginal rate of substitution (MRS) 
Attribute Treatment benefit 
% (95% CI) 
Risk of mild ADRs 
% (95% CI) 
Severe ADR - Very rare 50.58 (46.07, 57.87) -68.60 (-72.35, -63.98) 
Severe ADR - Rare -14.48 (-16.99, -12.77) 19.64 (17.49, 21.60) 
Severe ADR - Uncommon -36.10 (-41.24, -32.94) 48.96 (45.90, 51.25) 
Dose - Once a day  28.29 (25.18, 33.11) -38.36 (-42.50, -34.77) 
Dose - Twice a day -9.63 (-11.88, -8.14) 13.05 (11.15, 15.33) 
Dose - Four times a day -18.66 (-21.51, -16.67) 25.31 (22.95, 27.60) 
Treatment benefit  -1.36 (-1.49, -1.17) 
Common mild side-effects -0.74 (-0.85, -0.67)  
 504 
 505 
Appendix 1:  Psychosocial measures 
 
Psychological theory, model, 
variable 
Number 
of items 
{score} 
Item description  Scoring scale 
Sociocognitive theory:     
Theory of Planned Behaviour    
 Subjective norms  3-items 
{3-15} 
1. My doctor or nurse would approve of me taking my medicines regularly  
2. My wife/husband/partner would approve of me taking my medicines 
regularly  
3. Members of my family or close relatives would approve of me taking my 
medicines regularly 
5-point Likert scale: 
I agree a lot {5} 
I agree a little 
I neither agree or disagree 
I disagree a little  
I disagree a lot {1} 
 Barriers 1-items 
{3-15} 
1. Changes to my daily routine would make it more difficult for me to take 
my medicines regularly 
 Intention  2-items 
{2-10} 
1. It is likely that I will take my medicines regularly  
2. I intend to take my medicines regularly 
 Self-efficacy  2-items 
{2-10} 
1. Overall, how confident are you that you will always take your 
medications as prescribed? 
2. Overall, how confident are you that you will always take your 
medications at the prescribed times? 
 
5-point Likert scale: 
Not at all confident {1} 
Somewhat confident  
Very confident 
Extremely confident 
Completely confident {5} 
BRIGHT Environmental 
Constraints / Facilitators  
   
 Social support  7-items 
{0-35} 
1. Was there someone who reminded you to take your medicines? 
2. Was there someone who helped you to prepare the medicines? 
3. Was there someone who encouraged you to take your medicines 
correctly? 
4. Was there someone who gave practical tips to make it easier for you to 
take your medicines? 
5. Was there someone who adapted his or her own life habits (waking up, 
schedule…) to make it easier for you to take your medicines? 
5-point Likert scale: 
In the past 4 weeks … 
Never {0} 
Occasionally 
Sometimes 
Frequently  
All the time {4} 
 
Psychological theory, model, 
variable 
Number 
of items 
{score} 
Item description  Scoring scale 
6. Was there someone who understood the problems or discomfort that 
resulted from your medicines? 
7. Was there someone who reprimanded you because you didn’t take 
your medicines correctly? 
 BRIGHT Barriers  15-items 
{0-75} 
1. I ran out of medicines 
2. I was confused about which medicines to take  
3. I did not want other people to know that I have a health problem 
4. Something disrupted my daily medicine routine (e.g., I was on holiday) 
5. I was forgetful  
6. I could not afford to buy my medicines  
7. I felt depressed or overwhelmed 
8. I forgot to take my medicines with me when leaving the house 
9. I had too many medicines to take 
10. I suffered from the side effects of my medicine. 
11. I had to take too many different doses during the day 
12. I had problems swallowing the large pills of my medicines 
13. I did not like the taste of my medicines  
14. I had problems removing the medicines from the package 
15. I had problems drinking enough water to swallow the medicines 
5-point Likert scale: 
In the past year … 
Never {0} 
Occasionally 
Sometimes 
Frequently  
All the time {4} 
 
Self-regulation theory:    
Illness Representations    
 Illness consequences  1-item  
{0-10} 
1. How much does your illness affect your life? 
 
{0} - no affect at all  
{1 2 3 4 5 6 7 8 9} 
{10} - severely affects my 
life 
 
 Personal control  1-item  
{0-10} 
1. How much control do you feel you have over your illness? 
 
 
{0} - absolutely no control  
{1 2 3 4 5 6 7 8 9} 
{10} - extreme amount of 
control 
 
Psychological theory, model, 
variable 
Number 
of items 
{score} 
Item description  Scoring scale 
 Treatment control  1-item  
{0-10} 
1. How much do you think your treatment can help your illness? {0} - not at all  
{1 2 3 4 5 6 7 8 9} 
{10} - extremely helpful 
 
 Illness concern  1-item  
{0-10} 
1. How concerned are you about your illness? {0} - not at all concerned  
{1 2 3 4 5 6 7 8 9} 
{10} - extremely concerned 
 
Treatment Beliefs     
 Necessity of medicine  5-items 
{5-25} 
1. My health, at present, depends on these medicines  
2. My life would be impossible without these medicines 
3. Without these medicines I would be very ill 
4. My health in the future will depend on these medicines 
5. These medicines protect me from becoming worse 
 
5-point Likert scale: 
Strongly Agree {5} 
Agree 
Uncertain  
Disagree 
Strongly Disagree {1} 
 
 Concerns about medicine  6-items 
{6-30} 
1. Having to take these medicines worries me 
2. I sometimes worry about long-term effects of these medicines 
3. These medicines are a mystery to me 
4. These medicines disrupt my life 
5. I sometimes worry about becoming too dependent on these medicines 
6. These medicines give me unpleasant side effects 
 
 
5-point Likert scale: 
Strongly Agree {5} 
Agree 
Uncertain  
Disagree 
Strongly Disagree {1} 
 
 
 
 
Appendix 2.  Results of exploratory subgroup analysis of willingness to trade benefit or mild ADR 
with other attributes, presented by psychological theory, model, and factor  
 
 
Psychological theory 
Model 
Factor 
Trade-off  Subgroup  
MRS (95% confidence interval) 
Sociocognitive Theory 
Theory of Planned Behaviour 
Subjective norms: Perception that persistence 
is influenced by approval of others: doctor, 
nurse, partner, family. 
Higher influence of 
others 
 
Lower influence of 
others 
Mild ADR / Benefit -0.64 (-0.79, -0.56) -0.77 (-0.94, -0.68) 
Once daily dose / Benefit 23.25 (19.23, 29.40) 31.77 (27.06, 39.57) 
Twice daily dose / Benefit -8.39 (-11.58, -6.60) -9.70 (-13.27, -7.77) 
Four times a day dose / Benefit -14.86* (-18.26, -12.22) -22.07* (-26.78, -19.04) 
Very rare severe ADR / Benefit 50.91 (43.99, 60.89) 45.56 (39.24, 54.81) 
Rare severe ADR / Benefit -14.85 (-18.34, -12.39) -12.23 (-15.39, -9.77) 
Uncommon severe ADR / Benefit -36.06 (-43.10, -31.43) -33.33 (-39.89, -29.10) 
Benefit / Mild ADR -1.55 (-1.80, -1.27) -1.29 (-1.48, -1.06) 
Once daily dose / Mild ADR -36.14 (-42.92, -30.20) -41.01 (-47.13, -35.56) 
Twice daily dose / Mild ADR 13.04 (10.11, 16.67) 12.52 (10.00, 15.72) 
Four times a day dose / Mild ADR 23.10 (19.24, 26.99) 28.49 (24.98, 32.02) 
Very rare severe ADR / Mild ADR -79.14* (-86.43, -71.82) -58.81* (-64.10, -53.07) 
Rare severe ADR / Mild ADR 23.08* (19.59, 26.38) 15.78* (12.99, 18.62) 
Uncommon severe ADR / Mild ADR 56.06* (50.93, 60.76) 43.03* (39.34, 46.50) 
Barriers: Changes to daily routine would make 
it more difficult to take medicines regularly 
Higher barriers Lower barriers 
Mild ADR / Benefit -0.77 (-0.92, -0.67) -0.59 (-0.74, -0.52) 
Once daily dose / Benefit 30.33 (25.80, 36.85) 22.68 (18.57, 28.91) 
Twice daily dose / Benefit -9.49 (-12.40, -7.46) -8.24 (-11.43, -6.24) 
Four times a day dose / Benefit -20.84* (-24.68, -17.97) -14.44* (-17.94, -11.98) 
Very rare severe ADR / Benefit 46.27 (40.24, 55.68) 49.72 (43.71, 59.66) 
Rare severe ADR / Benefit -12.73 (-16.20, -10.49) -14.27 (-18.07, -11.86) 
Uncommon severe ADR / Benefit -33.53 (-39.42, -29.24) -35.45 (-42.26, -31.38) 
Benefit / Mild ADR -1.30* (-1.49, -1.09) -1.69* (-1.93, 1.36) 
Once daily dose / Mild ADR -39.43 (-44.74, -34.36) -38.23 (-45.75, -31.34) 
Twice daily dose / Mild ADR 12.34 (9.84, 15.07) 13.89 (10.28, 18.00) 
Four times a day dose / Mild ADR 27.09 (23.74, 30.44) 24.35 (19.98, 29.05) 
Very rare severe ADR / Mild ADR -60.15 (-64.87, -55.26) -83.81* (-91.51, -75.28) 
Rare severe ADR / Mild ADR 16.55 (14.18, 19.01) 24.06* (20.23, 27.60) 
Uncommon severe ADR / Mild ADR 43.59 (40.27, 46.51) 59.75* (54.13, 64.69) 
Intention: Likely to and/or intend to take 
medicines 
Higher intentions Lower intentions 
Mild ADR / Benefit -0.58* (-0.67, -0.52) -1.10* (-1.58, -0.86) 
Once daily dose / Benefit 20.06* (17.08, 24.18) 49.97* (38.10, 70.71) 
Twice daily dose / Benefit -6.67* (-8.77, -5.28) -16.64* (-24.72, -11.80) 
Four times a day dose / Benefit -13.39* (-15.72, -11.58) -33.34* (-46.34, -25.70) 
Very rare severe ADR / Benefit 40.26* (36.21, 45.97) 72.70* (56.78, 101.43) 
Rare severe ADR / Benefit -11.10* (-13.20, -9.48) -21.31* (-31.12, -16.06) 
Uncommon severe ADR / Benefit -29.16* (-33.11, -26.36) -51.39* (-71.54, -40.64) 
Benefit / Mild ADR -1.73* (-1.91, -1.50) -0.91* (-1.16, -0.64) 
Once daily dose / Mild ADR -34.64 (-40.38, -29.79) -45.36 (-52.58, -38.07) 
Twice daily dose / Mild ADR 11.51 (9.09, 14.70) 15.10 (11.37, 18.86) 
Four times a day dose / Mild ADR 23.12 (20.00, 26.34) 30.26 (25.79, 34.79) 
Very rare severe ADR / Mild ADR -69.53 (-74.41, -63.71) -65.99 (-73.01, -59.12) 
Rare severe ADR / Mild ADR 19.17 (16.56, 21.79) 19.34 (16.13, 22.86) 
Uncommon severe ADR / Mild ADR 50.36 (46.44, 53.33) 46.65 (42.12, 50.80) 
Self-efficacy: Confidence of taking medicines 
and/or at the prescribed times 
Higher confidence Lower confidence 
Mild ADR / Benefit -0.58* (-0.68, -0.52) -0.93* (-1.17, -0.78) 
Once daily dose / Benefit 21.31* (18.08, 25.71) 37.90* (30.67, 48.12) 
Twice daily dose / Benefit -7.26 (-9.63, -5.80) -12.34 (-16.92, -9.20) 
Four times a day dose / Benefit -14.06* (-16.46, -12.10) -25.56* (-32.06, -20.90) 
Very rare severe ADR / Benefit 44.11 (39.51, 50.42) 55.71 (47.02, 68.98) 
Rare severe ADR / Benefit -12.25 (-14.64, -10.40) -15.90 (-20.92, -12.80) 
Uncommon severe ADR / Benefit -31.86 (-36.06, -28.76) -39.81 (-49.21, -33.43) 
Benefit / Mild ADR -1.71 (-1.91, -1.47) -1.08* (-1.28, -0.86) 
Once daily dose / Mild ADR -36.50 (-42.82, -31.06) -40.92 (-46.81, -35.06) 
Twice daily dose / Mild ADR 12.43 (10.02, 16.01) 13.33 (10.27, 16.46) 
Four times a day dose / Mild ADR 24.07 (20.54, 27.42) 27.59 (23.95, 31.05) 
Very rare severe ADR / Mild ADR -75.55* (-82.07, -68.88) -60.14* (-66.36, -54.28) 
Rare severe ADR / Mild ADR 20.99 (18.03, 24.01) 17.16 (14.27, 20.21) 
Uncommon severe ADR / Mild ADR 54.56* (50.02, 58.65) 42.98* (39.13, 46.59) 
Sociocognitive Theory 
Bright:  Environmental Constraints / Facilitators 
Social support: Support from people in 
personal environment   
Higher social support  Lower social support  
Mild ADR / Benefit -0.64 (0.78, -0.56) -0.87 (-1.09, -0.74) 
Once daily dose / Benefit 25.76 (21.93, 32.10) 30.73 (24.84, 39.28) 
Twice daily dose / Benefit -8.44 (-11.46, -6.69) -10.67 (-14.99, -7.87) 
Four times a day dose / Benefit -17.32 (-21.13, -14.65) -20.06 (-25.21, -16.61) 
Very rare severe ADR / Benefit 42.01* (36.55, 50.80) 61.01* (51.62, 75.39) 
Rare severe ADR / Benefit -11.52 (-14.65, -9.44) -17.24 (-22.12, -14.04) 
Uncommon severe ADR / Benefit -30.49* (-36.48, -26.85) -43.76* (-53.90, -37.17) 
Benefit / Mild ADR -1.55* (-1.78, -1.29) -1.15 (-1.36, -0.92) 
Once daily dose / Mild ADR -40.02 (-46.49, -34.07) -35.39 (-41.63, -29.68) 
Twice daily dose / Mild ADR 13.11 (10.32, 16.79) 12.29 (9.40, 15.65) 
Four times a day dose / Mild ADR 26.91 (23.10, 30.77) 23.10 (19.43, 26.43) 
Very rare severe ADR / Mild ADR -65.25 (-71.52, -58.83) -70.25 (-76.67, -63.43) 
Rare severe ADR / Mild ADR 17.90 (14.93, 21.19) 19.86 (16.75, 23.03) 
Uncommon severe ADR / Mild ADR 47.36 (43.06, 51.18) 50.40 (45.86. 54.30) 
Self-regulation Theory 
Illness Representations 
Illness consequences: How much does your 
illness affect your life? 
Higher illness 
consequences 
Lower illness 
consequences 
Mild ADR / Benefit -0.77 (-0.94, -0.65) -0.64 (-0.76, -0.57) 
Once daily dose / Benefit 32.67 (27.43, 40.65) 22.58 (18.88, 28.03) 
Twice daily dose / Benefit -10.18 (-13.80, -7.87) -8.07 (-10.83, -6.17) 
Four times a day dose / Benefit -22.50* (-27.20, -19.10) -14.51* (-17.46, -12.22) 
Very rare severe ADR / Benefit 53.76 (45.87, 64.60) 43.36 (38.35. 51.07) 
Rare severe ADR / Benefit -15.24 (-19.24, -12.56) -12.16 (-14.94, -10.17) 
Uncommon severe ADR / Benefit -38.52 (-46.03, -33.07) -31.20 (-36.62, -27.56) 
Benefit / Mild ADR -1.31* (-1.53, -1.07) -1.56 (-1.76, -1.32) 
Once daily dose / Mild ADR -42.70 (-49.51, -36.83) -35.34 (-41.33, -29.57) 
Twice daily dose / Mild ADR 13.30 (10.37, 16.80) 12.63 (9.80, 15.77) 
Four times a day dose / Mild ADR 29.40 (25.49, 33.59) 22.71 (19.28, 25.93) 
Very rare severe ADR / Mild ADR -70.26 (76.95, -64.03) -67.84 (-73.64, -61.77) 
Rare severe ADR / Mild ADR 19.92 (16.77, 23.28) 19.03 (16.27, 22.06) 
Uncommon severe ADR / Mild ADR 50.34 (45.92, 54.69) 48.82 (44.94, 52.40) 
Personal control: How much control do you 
feel you have over your illness? illness  
Higher personal control Lower personal control 
Mild ADR / Benefit -0.83 (-1.01, -0.71) -0.60 (-0.72, -0.53) 
Once daily dose / Benefit 30.79 (24.97, 38.61) 24.53 (20.66, 30.01) 
Twice daily dose / Benefit -10.26 (-13.77, -7.52) -8.25 (-11.03, -6.39) 
Four times a day dose / Benefit -20.53 (-25.22, -17.20) -16.28 (-19.41, -13.96) 
Very rare severe ADR / Benefit 58.86* (50.95, 71.72) 39.59* (34.61, 47.11) 
Rare severe ADR / Benefit -16.64 (-20.96, -13.42) -11.08 (-14.01, -9.20) 
Uncommon severe ADR / Benefit -42.23* (-51.55, -36.86) -28.51* (-33.68, -25.19) 
Benefit / Mild ADR -1.21 (-1.41, -0.99) -1.67 (-1.89, -1.40) 
Once daily dose / Mild ADR -37.28 (-43.27, -31.74) -40.96 (-47.13, -34.53) 
Twice daily dose / Mild ADR 12.42 (9.48, 15.49) 13.78 (10.76, 17.26) 
Four times a day dose / Mild ADR 24.85 (21.23, 28.23) 27.18 (23.19, 30.67) 
Very rare severe ADR / Mild ADR -71.27 (-77.02, -65.43) -66.11 (-72.54, -59.50) 
Rare severe ADR / Mild ADR 20.14 (17.28, 23.25) 18.50 (15.62, 21.65) 
Uncommon severe ADR / Mild ADR 51.12 (47.16, 54.78) 47.61 (43.33, 51.46) 
Treatment control: How much do you think 
your treatment can help your illness? 
Higher treatment control Lower treatment control 
Mild ADR / Benefit -0.67 (-0.80, -0.60) -0.77 (-0.96, -0.65) 
Once daily dose / Benefit 24.35 (20.81, 29.84) 32.92 (27.15, 41.82) 
Twice daily dose / Benefit -8.56 (-11.27, -6.77) -10.19 (-14.33, -7.46) 
Four times a day dose / Benefit -15.79* (-18.89, -13.57) -22.74* (-28.29, -19.18) 
Very rare severe ADR / Benefit 49.91 (44.64, 58.58) 46.26 (39.16, 57.57) 
Rare severe ADR / Benefit -14.28 (-17.33, -12.30) -12.60 (-16.86, -9.92) 
Uncommon severe ADR / Benefit -35.64 (-41.91, -31.83) -33.66 (-41.27, -28.44) 
Benefit / Mild ADR -1.48 (-1.67, -1.25) -1.30 (-1.54, -1.04) 
Once daily dose / Mild ADR -36.12 (-42.10, -30.87) -42.90 (-49.92, -36.54) 
Twice daily dose / Mild ADR 12.69 (10.16, 15.96) 13.27 (10.07, 16.82) 
Four times a day dose / Mild ADR 23.43 (19.95, 26.71) 29.63 (25.71, 33.81) 
Very rare severe ADR / Mild ADR -74.05 (-79.96, -68.30) -60.27* (-66.63, -53.91) 
Rare severe ADR / Mild ADR 21.18 (18.46, 24.12) 16.41 (13.37, 20.09) 
Uncommon severe ADR / Mild ADR 52.87 (48.71, 56.44) 43.85* (39.62, 47.88) 
Illness concern: How concerned are you about 
your illness? 
Higher illness concern Lower illness concern 
Mild ADR / Benefit -0.90* (-1.10, -0.78) -0.51* (-0.61, -0.44) 
Once daily dose / Benefit 35.45* (29.60, 44.41) 19.98* (16.30, 25.06) 
Twice daily dose / Benefit -11.91 (-16.01, -9.30) -6.61 (-9.32, -4.77) 
Four times a day dose / Benefit -23.54* (-28.63, -20.11) -13.37* (-16.22, -11.12) 
Very rare severe ADR / Benefit 60.83* (52.54, 73.78) 36.33* (31.85, 43.05) 
Rare severe ADR / Benefit -17.17* (-21.47, -14.36) -10.07* (-12.86, -8.02) 
Uncommon severe ADR / Benefit -43.66* (-52.71, -37.86) -26.26* (-30.82, -23.13) 
Benefit / Mild ADR -1.11* (-1.29, -0.91) -1.98* (-2.25, -1.63) 
Once daily dose / Mild ADR -39.40 (-45.00, -34.82) -39.55 (-47.39, -32.48) 
Twice daily dose / Mild ADR 13.24 (10.82, 16.22) 13.09 (9.39, 17.41) 
Four times a day dose / Mild ADR 26.16 (23.07, 29.40) 26.47 (21.82, 30.81) 
Very rare severe ADR / Mild ADR -67.61 (-73.02, -62.02) -71.91 (-79.68, -63.11) 
Rare severe ADR / Mild ADR 19.08 (16.56, 21.61) 19.93 (16.15, 23.72) 
Uncommon severe ADR / Mild ADR 48.52 (44.84, 51.78) 51.98 (46.36, 56.85) 
Self-regulation Theory 
Treatment Beliefs 
Concerns about medicine Higher concerns about 
medicines 
Lower concerns about 
medicines 
Mild ADR / Benefit -1.01* (-1.33, -0.85 -0.53* (-0.63, -0.47 
Once daily dose / Benefit 41.48* (33.90, 54.45) 19.31* (16.38, 23.61) 
Twice daily dose / Benefit -13.34* (18.84, -10.10) -6.62* (-8.99, -5.13) 
Four times a day dose / Benefit -28.14* (-36.63, -23.24) -12.70* (-15.11, 10.84) 
Very rare severe ADR / Benefit 63.88* (52.54, 82.42) 40.06* (35.95, 46.87) 
Rare severe ADR / Benefit -17.70 (-23.79, -13.92) -11.31 (-13.94, -9.60) 
Uncommon severe ADR / Benefit -46.17* (-59.47, -38.47) -28.75* (-33.10, -25.81) 
Benefit / Mild ADR -0.99* (-1.18, -0.75) -1.90* (-2.12, -1.60) 
Once daily dose / Mild ADR -40.89 (-46.88, -34.80) -36.77 (-43.18, -30.91) 
Twice daily dose / Mild ADR 13.15 (10.18, 16.36) 12.60 (9.62, 16.13) 
Four times a day dose / Mild ADR 27.74 (24.20, 31.29) 24.17 (20.44, 27.60) 
Very rare severe ADR / Mild ADR -62.97* (-68.84, -57.12) -76.27* (-83.20, -69.36) 
Rare severe ADR / Mild ADR 17.45 (14.46, 20.80) 21.53 (18.31, 24.93) 
Uncommon severe ADR / Mild ADR 45.52* (41.84, 48.88) 54.74* (49.92, 58.89) 
Notes. MRS. Marginal Rate of Substitution between attributes.  * Indicates statistically significant sub-
groups (p<0.004, critical p-value for multiple comparison for 12 subgroups). Spilt sample analysis not 
significantly different to base case for:  Sociocognitive theory, BRIGHT Barriers: problems with taking 
medicines or taking them on time p=0.0093; and, Self-regulation Theory, Treatment beliefs:  beliefs 
about the necessity of medicine p=0.0645; therefore marginal rates of substitution were not 
calculated.   
 
